389 related articles for article (PubMed ID: 36940189)
1. Targeted Protein Degradation through E2 Recruitment.
Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
[TBL] [Abstract][Full Text] [Related]
2. Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1.
Meyers M; Cismoski S; Panidapu A; Chie-Leon B; Nomura DK
ACS Chem Biol; 2024 Jan; 19(1):58-68. PubMed ID: 38192078
[TBL] [Abstract][Full Text] [Related]
3. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.
Hong SH; Divakaran A; Osa A; Huang OW; Wertz IE; Nomura DK
ACS Chem Biol; 2024 Feb; 19(2):442-450. PubMed ID: 38305738
[TBL] [Abstract][Full Text] [Related]
5. Targeted Protein Degradation through Recruitment of the CUL4A Complex Adaptor Protein DDB1.
Meyers M; Cismoski S; Panidapu A; Chie-Leon B; Nomura DK
bioRxiv; 2023 Aug; ():. PubMed ID: 37614621
[TBL] [Abstract][Full Text] [Related]
6. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.
Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK
ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647
[TBL] [Abstract][Full Text] [Related]
7. Chemoproteomics-enabled discovery of a covalent molecular glue degrader targeting NF-κB.
King EA; Cho Y; Hsu NS; Dovala D; McKenna JM; Tallarico JA; Schirle M; Nomura DK
Cell Chem Biol; 2023 Apr; 30(4):394-402.e9. PubMed ID: 36898369
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.
Henning NJ; Manford AG; Spradlin JN; Brittain SM; Zhang E; McKenna JM; Tallarico JA; Schirle M; Rape M; Nomura DK
J Am Chem Soc; 2022 Jan; 144(2):701-708. PubMed ID: 34994556
[TBL] [Abstract][Full Text] [Related]
9. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
10. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs.
Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW
J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885
[TBL] [Abstract][Full Text] [Related]
11. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation.
Hong SH; Osa A; Huang OW; Wertz IE; Nomura DK
bioRxiv; 2023 Nov; ():. PubMed ID: 37904950
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs.
Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J
Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
14. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
15. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.
Verma R
Adv Exp Med Biol; 2021; 1322():339-357. PubMed ID: 34258747
[TBL] [Abstract][Full Text] [Related]
17. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
18. Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.
Siepe DH; Picton LK; Garcia KC
ACS Synth Biol; 2023 Apr; 12(4):1081-1093. PubMed ID: 37011906
[TBL] [Abstract][Full Text] [Related]
19. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
20. [Application of PROTACs in Hematological Malignancies--Review].
Jia YN; Mi YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1921-1924. PubMed ID: 38071084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
